Indication
Respiratory Tract Diseases
18 clinical trials
25 products
4 drugs
Clinical trial
A Phase IIa, Double-Blind, Randomized, Multi-Center Study Comparing MRG-001 to Placebo in Patients With Acute Respiratory Distress SyndromeStatus: Not yet recruiting, Estimated PCD: 2026-02-01
Product
MRG-001Product
RESP301Clinical trial
A Randomised Multicentre Post-exposure Prophylaxis Clinical Trial Evaluating RESP301, an Inhaled Therapy for Treatment of Lung Infections, for Prevention of Onward Transmission of Viral Infections Including SARS-CoV-2 to Household MembersStatus: Withdrawn, Estimated PCD: 2022-01-01
Product
Standard of CareProduct
VapendavirClinical trial
A Trial in Participants With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate the Impact of Vapendavir on the Development of Lower Respiratory Tract Symptoms Following Rhinovirus ChallengeStatus: Recruiting, Estimated PCD: 2024-12-30
Product
PlaceboClinical trial
Randomized, Blinded, Positive-controlled Phase Ib Clinical Trial for Preliminary Evaluation of Safety and Immunogenicity of Recombinant Pneumococcal Protein Vaccine in Adults Aged 50 Years and Older After VaccinationStatus: Active (not recruiting), Estimated PCD: 2023-12-11
Product
PPV23Product
PBPVClinical trial
A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Adults 65 Years of Age and OlderStatus: Completed, Estimated PCD: 2019-05-17
Product
Quadrivalent VLP VaccineProduct
Fluarix QuadrivalentClinical trial
A Phase III, Multi-centre, Randomized, Rater- and Patient-blind, Placebo- and Active-controlled, Parallel Group Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily (Active Test Treatment), Ambroxol Hydrochloride 30 mg Twice Daily (Active Control Treatment) and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus SecretionsStatus: Completed, Estimated PCD: 2021-01-23
Product
Ambroxol hydrochlorideProduct
N-acetylcysteineClinical trial
A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients With EGFR-Mutant Non-Small Cell Lung CancerStatus: Terminated, Estimated PCD: 2022-12-09
Clinical trial
A Phase Ⅰa Randomized,Double-Blind, Placebo-controlled Clinical Trial to Preliminary Evaluate the Safety and Immunogenicity of Protein Based Pneumococcal Vaccine（PBPV） in Healthy People Aged Between 18 and 49 Years OldStatus: Completed, Estimated PCD: 2021-05-30
Product
aH5N6cClinical trial
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59-adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or UnprimedStatus: Completed, Estimated PCD: 2022-10-24
Product
RSV VaccineClinical trial
A Randomized, Double-blind, Placebo-controlled Phase 2b Study to Assess the Efficacy, Immunogenicity and Safety of an Ad26.RSV.preF-based Regimen in the Prevention of RT PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and OlderStatus: Completed, Estimated PCD: 2022-06-06
Product
carboplatinProduct
pemetrexedProduct
BLU-701Product
osimertinibProduct
CC-90001Clinical trial
A Phase 2, 24-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary FibrosisStatus: Terminated, Estimated PCD: 2021-12-24
Clinical trial
A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults 18-64 Years of AgeStatus: Completed, Estimated PCD: 2018-05-02
Clinical trial
A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsStatus: Terminated, Estimated PCD: 2022-05-16
Product
AlectinibClinical trial
A Phase II Study of Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)Status: Recruiting, Estimated PCD: 2025-11-24
Drug
AtezolizumabClinical trial
A Phase Ⅱ Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Extensive-Stage Oligometastatic Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2026-06-30
Drug
AdebrelimabProduct
Carboplatin/CisplatinProduct
EtoposideClinical trial
Validation Protocol for The Clinical Use of Convalescent Plasma for Hospitalized Patients With COVID-19. A Prospective Study at a Hospital in Southern Brazil.Status: Completed, Estimated PCD: 2022-04-04
Product
Convalescent plasmaProduct
Standard of careClinical trial
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism: a Multicenter Randomized Placebo-controlled Non-inferiority TrialStatus: Recruiting, Estimated PCD: 2026-05-01
Drug
RivaroxabanDrug
VarlilumabClinical trial
Daily Vitamin D for Sickle-cell Respiratory ComplicationsStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Product
Vitamin D3